$HEPA News

Hepion Pharmaceuticals Receives FDA Feedback Supporting a Path to Demonstrating Prophylactic Protection for GV104 Against Fentanyl-Induced Cardiac Arrest

Hepion Pharmaceuticals Receives Positive FDA Response on GV104 in Gambling Disorder, a Condition With No Approved Medication

Hepion Pharmaceuticals Completes Acquisition of Gravitas Life Sciences and Provides Corporate Update

Hepion Pharmaceuticals In-Licenses ctRNA Biomarker Assay to Facilitate Early Diagnosis and Surveillance of Hepatocellular Carcinoma

Hepion Pharmaceuticals Announces Dr. Kaouthar Lbiati as Interim Chief Executive Officer

Hepion Pharmaceuticals Announces Receipt of Delisting Notification from Nasdaq

Hepion Pharmaceuticals Announces Receipt Of Delisting Notification From Nasdaq

Hepion Pharmaceuticals Executes Binding Letter of Intent with New Day Diagnostics to Commercialize Diagnostic Tests for Celiac Disease, Respiratory Multiplex, H. Pylori and HCC

Hepion Pharmaceuticals shares are trading higher after the company announced it signed a binding letter of intent with New Day Diagnostics to license diagnostic tests for celiac disease.

Hepion Pharmaceuticals Executes Binding Letter Of Intent With New Day Diagnostics LLC To In-License Diagnostic Tests For Celiac Disease, Respiratory Multiplex, H. Pylori And HCC

Hepion Pharmaceuticals Announces Reverse Stock Split

Hepion Pharmaceuticals shares are trading lower after the company announced a 1-for-50 reverse stock split.

Hepion Pharmaceuticals Announces 1-For-50 Reverse Stock Split Effective March 17, 2025

Hepion Pharmaceuticals Announces $9.0 Million Public Offering

Hepion Pharmaceuticals shares are trading lower after the company announced a $9 million public offering.

Hepion Pharmaceuticals Announces $9M Public Offering

Hepion Pharmaceuticals, Inc. Announces Termination of Merger Agreement with Pharma Two B Ltd.

Hepion Pharmaceuticals shares are trading lower. The company announced the termination of a merger agreement with Pharma Two B.

Hepion Pharmaceuticals Announces Termination Of Merger Agreement With Pharma Two B Ltd.; Neither Party Will Be Required To Pay The Other A Termination Fee As A Result Of The Mutual Decision To Terminate The Agreement

Pharma Two B Announces Poster Presentation on P2B001 at the Annual Meeting of the Parkinson’s Disease Study Group